Deepa Rangachari

2.9k total citations · 1 hit paper
68 papers, 1.8k citations indexed

About

Deepa Rangachari is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Deepa Rangachari has authored 68 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Deepa Rangachari's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (23 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Deepa Rangachari is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (23 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Deepa Rangachari collaborates with scholars based in United States, Japan and Israel. Deepa Rangachari's co-authors include Daniel B. Costa, Paul A. VanderLaan, Mark S. Huberman, Meghan Shea, Susumu Kobayashi, Erik Folch, Kartik Sehgal, Suzanne E. Dahlberg, Eric T. Wong and Erik J. Uhlmann and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Oncologist.

In The Last Decade

Deepa Rangachari

66 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

2015 348 citations Deepa Rangachari, Norihiro Yamaguchi et al. Lung Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deepa Rangachari United States	22	1.3k	1.1k	459	430	124	68	1.8k
Pascale Tomasini France	22	1.1k 0.8×	1.1k 1.0×	465 1.0×	425 1.0×	121 1.0×	109	1.8k
Jessica Menis Italy	21	1.1k 0.8×	1.2k 1.0×	381 0.8×	363 0.8×	121 1.0×	76	1.9k
Christine Lydon United States	18	1.2k 0.9×	1.0k 0.9×	658 1.4×	435 1.0×	215 1.7×	30	1.8k
Cristina Queralt Spain	19	1.2k 0.9×	1.0k 0.9×	736 1.6×	501 1.2×	115 0.9×	46	1.9k
Daniel T. Milton United States	16	1.9k 1.4×	1.6k 1.5×	587 1.3×	383 0.9×	106 0.9×	27	2.4k
Patrick Peterson United States	21	2.2k 1.6×	1.8k 1.6×	472 1.0×	310 0.7×	78 0.6×	55	2.6k
Jacob J. Adashek United States	24	506 0.4×	816 0.7×	338 0.7×	416 1.0×	143 1.2×	106	1.5k
Juergen Wolf Germany	22	914 0.7×	1.0k 0.9×	630 1.4×	282 0.7×	334 2.7×	92	1.8k
Karina Vera United States	10	762 0.6×	723 0.6×	816 1.8×	287 0.7×	142 1.1×	17	1.7k
Miso Kim South Korea	25	710 0.5×	1.2k 1.1×	292 0.6×	208 0.5×	145 1.2×	87	1.7k

Countries citing papers authored by Deepa Rangachari

Since Specialization

Citations

This map shows the geographic impact of Deepa Rangachari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepa Rangachari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepa Rangachari more than expected).

Fields of papers citing papers by Deepa Rangachari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepa Rangachari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepa Rangachari. The network helps show where Deepa Rangachari may publish in the future.

Co-authorship network of co-authors of Deepa Rangachari

This figure shows the co-authorship network connecting the top 25 collaborators of Deepa Rangachari. A scholar is included among the top collaborators of Deepa Rangachari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepa Rangachari. Deepa Rangachari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patell, Rushad, Poorva Bindal, Jason A. Freed, et al.. (2025). A Multicenter Feasibility Study of a Novel Curriculum for Oncology Trainees Regarding Medical Cannabis. Journal of the National Comprehensive Cancer Network. 23(3). 82–89.

Gunturu, Krishna S., Hollis Viray, Andrew J. Piper‐Vallillo, et al.. (2024). Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer. 198. 108023–108023. 1 indexed citations

Viray, Hollis, Andrew J. Piper‐Vallillo, Page Widick, et al.. (2024). A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers. 16(6). 1079–1079. 4 indexed citations

Meador, Catherine B., Subba R. Digumarthy, Beow Y. Yeap, et al.. (2024). Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes. Clinical Cancer Research. 31(1). 25–34. 1 indexed citations

Kobayashi, Ikei S., Hollis Viray, Deepa Rangachari, et al.. (2023). The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports. 5(1). 100614–100614. 6 indexed citations

Kobayashi, Ikei S., Shriram K. Sundararaman, Meghan Lee, et al.. (2023). EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Lung Cancer. 181. 107250–107250. 3 indexed citations

Chen, Zsu‐Zsu, et al.. (2023). Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the Literature. JTO Clinical and Research Reports. 4(2). 100463–100463. 1 indexed citations

Academia, Emmeline C., Hollis Viray, Deepa Rangachari, et al.. (2023). EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Translational Lung Cancer Research. 12(7). 1590–1610. 16 indexed citations

Roberts, Daniel A., K. Leahy, Sara Giordano, et al.. (2022). Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future. JCO Oncology Practice. 19(6). e927–e934. 5 indexed citations

10.

Cooper, Alissa J., Yoshihisa Kobayashi, Dewey Kim, et al.. (2020). Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(15). 4072–4079. 14 indexed citations

11.

VanderLaan, Paul A., Deepa Rangachari, & Daniel B. Costa. (2020). The rapidly evolving landscape of biomarker testing in non–small cell lung cancer. Cancer Cytopathology. 129(3). 179–181. 19 indexed citations

12.

Ricciuti, Biagio, Sarah P. Hammond, Francisco M. Marty, et al.. (2020). Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 145. 181–185. 31 indexed citations

13.

Farago, Anna F., B.Y. Yeap, Rebecca S. Heist, et al.. (2019). OA15.01 Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 1 indexed citations

14.

Rangachari, Deepa, Ciric To, Paul A. VanderLaan, et al.. (2019). EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Journal of Thoracic Oncology. 14(11). 1995–2002. 69 indexed citations

15.

Jorge, Susan E., Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, et al.. (2018). EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clinical Cancer Research. 24(24). 6548–6555. 51 indexed citations

16.

Shea, Meghan, et al.. (2018). Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treatment and Research Communications. 15. 17–20. 11 indexed citations

17.

Torous, Vanda F., et al.. (2018). PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology. 7(3). 133–141. 53 indexed citations

18.

VanderLaan, Paul A., Deepa Rangachari, Susan M. Mockus, et al.. (2017). P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes. Journal of Thoracic Oncology. 12(1). S506–S506. 1 indexed citations

19.

Rangachari, Deepa, Lauren Drake, Mark S. Huberman, et al.. (2016). Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treatment and Research Communications. 9. 41–43. 7 indexed citations

20.

Rangachari, Deepa, Norihiro Yamaguchi, Paul A. VanderLaan, et al.. (2015). Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer. 88(1). 108–111. 348 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact